News
-
-
-
COMMUNIQUÉ DE PRESSE
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division
Kuros Biosciences USA, Inc. announces exclusive strategic agreement with Medtronic spinal division, transforming trial into a 5-year alliance, expanding MagnetOs bone grafting technology in U.S. spine market -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Kuros reports 149% increase in direct MagnetOs sales and exceeds cash flow breakeven in the first nine months of 2024
Kuros Biosciences reports 149% increase in direct MagnetOs sales and surpasses cash flow breakeven in the first nine months of 2024. Company's financial highlights and future outlook highlighted -